

- promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. *J Hepatol* 2011;54:887-893.
41. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *HEPATOLOGY* 2003;37:600-609.
  42. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. *J Viral Hepat* 2009;16:75-90.
  43. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. *Gastroenterology* 2010;139:821-827.
  44. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. *J Hepatol* 2011;54:415-421.
  45. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. *Am J Gastroenterol* 2002;97:2880-2885.
  46. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006;130:1636-1642.
  47. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 2004;53:406-412.
  48. Kahler CM, Schratzberger P, Kaufmann G, Hochleitner B, Bechter O, Gotsch C, et al. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. *Regul Pept* 2002;105:35-46.
  49. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, DeMino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. *Gastroenterology* 2011;141:1220-1230.
  50. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. *Dig Dis Sci* 2008;53:815-822.

